Individual Patient Compassionate Use of Mirdametinib

SpringWorks Therapeutics

Status

Conditions: Other MAP-K Pathway Driven Diseases; Neurofibromatosis Type 1-Associated Plexiform Neurofibromas; Histiocytic Neoplasm

Treatments: Drug: Mirdametinib (MEK Inhibitor)

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT05028166

MEK-NF1-701

Details and patient eligibility

About

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.

Sex: All

Ages: 2+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted.
• Patient does not qualify to participate in an ongoing clinical trial.